According to the Legislative Budget Board (LBB), no significant fiscal implication to the State is anticipated from HB 712. The LBB assumes that any costs associated with implementing the bill could be absorbed using existing resources.

For local governments, the LBB likewise anticipates no significant fiscal implication. The fiscal note does not identify a major state or local cost driver, nor does it project a measurable savings or revenue gain.

The affected agencies listed by the LBB include the Teacher Retirement System, Employees Retirement System, Texas Department of Insurance, Health and Human Services Commission, Texas A&M University System, and University of Texas System Administration. That agency list reflects the bill’s reach across public employee health plans, Medicaid-related programs, insurance regulation, and higher education system plans, but the LBB does not anticipate implementation costs rising to a significant level.

Texas Policy Research recommends that lawmakers vote NO on HB 712 as it seeks to remove out-of-pocket costs for certain prostate cancer screening benefits by prohibiting covered health benefit plans from charging a premium, copayment, coinsurance, deductible, or any other form of cost sharing for covered prostate cancer detection services. The bill analysis frames the measure as an effort to reduce financial barriers to early prostate cancer detection, especially for underserved populations.

Despite that public health objective, the bill expands the size and scope of government by increasing state control over health benefit design. It does not merely encourage screening or fund targeted access for high-risk populations. Instead, it directs a broad range of private and public health plans to structure coverage in a specific way. The bill expands applicability to Lloyd’s plans, reciprocal and interinsurance exchanges, small employer health benefit plans, standard consumer choice plans, state employee and teacher plans, school district group health coverage, Medicaid, CHIP, certain regional or local health care programs, and self-funded professional employer organization plans.

The bill also increases regulatory burden on insurers, employers, public plans, and other plan sponsors by limiting their ability to design benefits, price coverage, and use cost sharing to manage utilization and premiums. A prohibition on deductibles, copayments, coinsurance, and other cost sharing may make the covered service free at the point of care, but it does not make the service free. The cost is shifted into the broader insurance system, where it may be reflected in premiums, plan design changes, employer costs, or taxpayer-supported health coverage programs.

The direct taxpayer impact appears limited under the official fiscal note. The Legislative Budget Board found that no significant fiscal implication to the state is anticipated and assumed that any costs could be absorbed using existing resources. The LBB also found no significant fiscal implication to units of local government. However, that finding does not eliminate taxpayer concern. The bill applies to state and public-sector health plans, Medicaid, CHIP, school district coverage, and local or regional health care programs, meaning any longer-term increase in utilization or plan costs could eventually be borne by taxpayers, public employers, or enrollees if existing assumptions prove incomplete.

The principal liberty concern is the precedent created by another state-mandated, disease-specific insurance benefit. A limited-government approach should be cautious about using state law to dictate benefit structure for particular services, even when the service is medically valuable. Each new mandate narrows the range of plan options available to consumers and employers and makes it easier for future legislatures to add additional mandated benefits, further reducing market flexibility.

The bill’s goal of improving access to early prostate cancer detection is understandable, but the mechanism relies on expanded state control, broader insurance mandates, and cost shifting rather than a narrowly tailored approach. Lawmakers concerned with limited government, taxpayer exposure, and regulatory burden should oppose the bill as written.